testing and recommendations: egfr-mutated stage iv nsclc
Published 4 years ago • 172 plays • Length 3:36Download video MP4
Download video MP3
Similar videos
-
4:27
molecular testing beyond egfr and alk in stage iv nsclc
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
2:19
patient summary: egfr-mutant stage 4 lung adenocarcinoma
-
1:05:12
new horizons in egfr-mutated nsclc: broadening the impact of precision testing
-
5:53
targeted therapy in non-small cell lung cancer
-
4:28
mutation testing for advanced lung cancer
-
1:33:47
oncology cancer treatment update - 23 aug 2024
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
9:23
mutation testing for all patients with nsclc
-
41:59
testing for common and uncommon egfr mutations to guide egfr-targeted therapy in nsclc
-
1:04
molecular testing in egfr mutant driven nsclc
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
9:30
egfr testing for nsclc
-
59:19
precision oncology in early-stage lung cancer, with adjuvant egfr-targeted therapy leading the way
-
1:02:40
new milestones and changing standards of care in early egfr-mutated nsclc
-
5:00
case 2: testing for egfr in lung adenocarcinoma
-
3:55
egfr-mutant nsclc: optimizing therapy selection